Tasso, a leader in patient-centric blood collection, launched its next-generation dried blood spot (DBS) sample collection system. This system combines the new Tile-T20 cartridge with the Tasso Mini device, enabling precise and convenient DBS sample collection for clinical trials and sports anti-doping. The system aims to improve the patient experience and streamline the sample collection process.
This development is crucial for the pharmaceutical industry and patients alike. Simplified, virtually painless at-home collection methods can significantly improve patient compliance and retention in clinical trials, particularly for those with limited mobility or access to clinical sites. This increased participation can accelerate trial timelines, leading to faster drug development and ultimately quicker access to new therapies for patients. Furthermore, the precise, volumetrically-controlled samples enhance the quality and reliability of data collected, which is critical for accurate research outcomes.
The Tile-T20 cartridge, designed for use with patient-centric lancets, collects four precise blood samples suitable for quantitative analysis. It is compatible with all of Tasso’s existing blood collection devices, including the new Tasso Mini. The Tasso Mini is a minimally invasive lancet, designed for frequent use and sensitive populations. Both the Tile-T20 and Tasso Mini have received necessary regulatory clearances (FDA 510(k) and CE Marking).
This new system from Tasso represents a significant advancement in DBS technology. By improving the patient experience and streamlining the collection process, it has the potential to transform how clinical trials are conducted, leading to more efficient drug development and improved patient outcomes. Wider adoption of this technology could ultimately reshape the landscape of clinical research and diagnostics, making healthcare more accessible and convenient.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
